These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36874318)

  • 1. The Effect of Sacubitril-Valsartan on Ventricular Arrhythmia Burden in Patients With Heart Failure With Reduced Ejection Fraction.
    Medeiros P; Coelho C; Costa-Oliveira C; Rocha S
    Cureus; 2023 Feb; 15(2):e34508. PubMed ID: 36874318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
    Acquaro M; Scelsi L; Pasotti B; Seganti A; Spolverini M; Greco A; Schirinzi S; Turco A; Sanzo A; Savastano S; Rordorf R; Ghio S
    Vascul Pharmacol; 2023 Oct; 152():107196. PubMed ID: 37467909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices.
    de Diego C; González-Torres L; Núñez JM; Centurión Inda R; Martin-Langerwerf DA; Sangio AD; Chochowski P; Casasnovas P; Blazquéz JC; Almendral J
    Heart Rhythm; 2018 Mar; 15(3):395-402. PubMed ID: 29146274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
    Curtain JP; Jackson AM; Shen L; Jhund PS; Docherty KF; Petrie MC; Castagno D; Desai AS; Rohde LE; Lefkowitz MP; Rouleau JL; Zile MR; Solomon SD; Swedberg K; Packer M; McMurray JJV
    Eur J Heart Fail; 2022 Mar; 24(3):551-561. PubMed ID: 34969175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.
    Guerra F; Ammendola E; Ziacchi M; Aspromonte V; Pellegrino PL; Del Giorno G; Dell'Era G; Pimpini L; Santoro F; Floris R; Stronati G; Nigro G; Paolisso P; Guido A; Maglia G; Brunetti ND; Carbone A; Gravellone M; Antonicelli R; Cannone M; Accogli M; Dello Russo A; Palmisano P
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1835-1842. PubMed ID: 34279677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Add-on Sacubitril/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy to a Similar Extent as in Heart Failure Patients Without Resynchronization.
    Szabó KM; Tóth A; Nagy L; Rácz V; Pólik Z; Hodosi K; Nagy AC; Barta J; Borbély A; Csanádi Z
    Cardiol Ther; 2024 Mar; 13(1):149-161. PubMed ID: 38216822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wang R; Ye H; Ma L; Wei J; Wang Y; Zhang X; Wang L
    Front Cardiovasc Med; 2022; 9():890481. PubMed ID: 35859597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(13):1-60. PubMed ID: 23074464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up.
    Paolini C; Mugnai G; Dalla Valle C; Volpiana A; Ferraglia A; Frigo AC; Bilato C
    Int J Cardiol Heart Vasc; 2021 Aug; 35():100821. PubMed ID: 34179333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
    Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
    ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study.
    Aqel R; Alzughayyar TZ; Abukhalaf SA; Misk RA; Zalloum JS
    J Renin Angiotensin Aldosterone Syst; 2021; 2021():1829873. PubMed ID: 35027945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart failure as a substrate and trigger for ventricular tachycardia.
    Alvarez CK; Cronin E; Baker WL; Kluger J
    J Interv Card Electrophysiol; 2019 Dec; 56(3):229-247. PubMed ID: 31598875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the right ventricular lead position on clinical outcome and on the incidence of ventricular tachyarrhythmias in patients with CRT-D.
    Kutyifa V; Bloch Thomsen PE; Huang DT; Rosero S; Tompkins C; Jons C; McNitt S; Polonsky B; Shah A; Merkely B; Solomon SD; Moss AJ; Zareba W; Klein HU
    Heart Rhythm; 2013 Dec; 10(12):1770-7. PubMed ID: 23973954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
    Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
    Amin OA; Alaarag AF
    Anatol J Cardiol; 2021 Mar; 25(3):163-169. PubMed ID: 33690130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register.
    Pastore MC; Mandoli GE; Giannoni A; Benfari G; Dini FL; Pugliese NR; Taddei C; Correale M; Brunetti ND; Carluccio E; Mengoni A; Guaricci AI; Piscitelli L; Citro R; Ciccarelli M; Novo G; Corrado E; Pasquini A; Loria V; Degiovanni A; Patti G; Santoro C; Moderato L; Malagoli A; Emdin M; Cameli M; ; Rosa G; Magnesa M; Mazzeo P; De Carli G; Bellino M; Iuliano G; Casciano O; Binno S; Canepa M; Tondi S; Cicoira M; Mega S
    Eur Heart J Open; 2022 Jan; 2(1):oeab046. PubMed ID: 35919657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.